A retrospective cohort study analyzed data from 18,047 adults aged 18 to 45 across 112 U.S. health systems. These participants had a diagnosis of opioid dependence or opioid use disorder. The researchers looked at different treatment approaches, including no treatment, buprenorphine alone, methadone alone, psychotherapy alone, and combinations of these options.
The analysis followed patients for 12 months to see who achieved remission. Buprenorphine alone was linked to significantly higher remission rates compared to no treatment. Methadone alone also showed a positive association with remission. Psychotherapy sessions lasting 30, 45, or 60 minutes were each independently associated with better outcomes than receiving no treatment.
The strongest effect was seen when buprenorphine was combined with psychotherapy. This combination yielded the highest association with remission. The study also noted that anxiety diagnoses and gabapentinoid prescriptions were positively associated with remission, while benzodiazepine co-prescription was negatively associated. Safety concerns or adverse events were not reported in the available data.
This research supports policies promoting equitable access to both medication for opioid use disorder and behavioral health supports. Readers should understand this is a retrospective study, which means it observes past data rather than testing interventions in real time. The findings suggest a link between these treatments and better outcomes, but they do not prove that one specific method causes remission in every case.